Antibody–Drug Conjugates in the Treatment of Cancer and Mechanisms of Ocular Toxicity

Anthony Perissinotti, PharmD, BCOP describes the mechanism of corneal toxicity from antibody–drug conjugates used in the treatment of patients with cancer.
Anthony Perissinotti, PharmD, BCOP
Format: Microsoft PowerPoint (.ppt)
File Size: 391 KB
Released: December 15, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
GlaxoSmithKline

Related Content

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on the integration of CAR T-cell therapy for leukemias, lymphomas, and myeloma

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 18, 2021

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy for leukemias, lymphomas, and myeloma

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 11, 2021

Downloadable slides from Clinical Care Options (CCO) with key takeaway points on newly approved agents for multiple myeloma

Beth Faiman, PhD, MSN, APRN-BC, AOCN Charise Gleason, MSN, NP-BC, AOCNP Released: February 2, 2021

Downloadable slides from Clinical Care Options (CCO) with nurse expert’s insights on available treatments, new approvals, and adverse event managements in patients with multiple myeloma

Beth Faiman, PhD, MSN, APRN-BC, AOCN Charise Gleason, MSN, NP-BC, AOCNP Released: January 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue